Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03535740
Title A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Ariad Pharmaceuticals
Indications

lung non-small cell carcinoma

Therapies

Brigatinib

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | AUT | AUS

Additional content available in CKB BOOST